TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1 

MoonRISe-1: Phase 3 study of TAR-210, an erdafitinib intravesical delivery system, versus intravesical chemotherapy in patients with intermediate-risk non–muscle-invasive bladder cancer with susceptible FGFR alterations.